Bio Vet Innovator Magazine

Volume 2 (Issue 7) JULY 2025

OPEN ACCESS WORLD ZOONOSES DAY – 06 JULY POPULAR ARTICLE

Unleashing the Truth: Insights into Canine Mammary Tumours

Amit Kumar[1]*, Priyanka Syal[2] and Ravindran R[3]
[1]*Assistant Professor, Department of Veterinary Surgery and Radiology,*
[2]*Assistant Professor, Department of Veterinary Pathology,*
[3]*Professor, Department of Veterinary Pathology,*
College of Veterinary Science, Rampura Phul -151103, Bathinda, GADVASU, Punjab, India
***Corresponding Author:** amitdhartterwal@gmail.com
DOI: https://doi.org/10.5281/zenodo.16661325

Received: July 28, 2025
Published: July 30, 2025

Introduction:

A tumour or neoplasm is an aberrant tissue proliferation resulting from unregulated, progressive cellular division that serves no physiological purpose. Based on the likelihood to spread and invade other distant regions, neoplasms are typically categorized as either benign or malignant. In addition to having a distinct capsule, benign tumours do not typically spread to other parts of the body. Conversely, malignant tumours are recognized for their ability to invade distant tissues through metastasis, multiply, and lead to life-threatening illnesses. Approximately 54.17% of mammary gland tumours in female dogs are malignant and capable of metastasizing to various organs, while 45.83% are benign (Ray *et al.,* 2021).It is widely recognized that canine mammary gland tumours are a heterogeneous disease and present a significant challenge for veterinarians.

Over the past few years, there has been a rise in the number of cases of cancer in canines. Cancer is a primary cause of mortality in companion animals, particularly in dogs, where neoplasms occur twice as frequently as in humans (Tanaka *et al.,* 2020; Rungsipipat *et al.,* 2003). According to Bhanderi *et al.* (2022), cutaneous tumours account for the largest percentage of all documented canine tumour cases (33.66%), followed by mammary gland tumours. In dogs, neoplasms of the epidermis, sexual organs, and mammary gland are more prevalent than those of the muscles or gastrointestinal system (Arya *et al.,*2018).

Occurrence of these tumours are higher in those dogs in which ovariohysterectomy is not performed at early age. Mammary neoplasia has 0.5% risk of occurring in dogs who are spayed before their first estrous cycle whereas the risk rises to 8% after the first estrus and continuously increases to 26% after second estrus (Schneider et al., 1969). At 9 to 11 years of age, female dogs have maximum risk of developing mammary tumors.

Canine mammary neoplasm has complex etiologies characterized by significant diversity, including genetic variables as internal host influences, while dietary and environmental contaminants, such as pyrethroids, serve as external host factors that diminish an individual's immune response (Andrade *et al.,* 2010).

In dogs with mammary tumours, hemato-biochemical measures reveal an insignificant drop in mean hemoglobin, PCV, and TEC. The mean leukogram of mammary carcinoma cases demonstrated an insignificant increase in the total white blood cell count and neutrophils, as well as a decrease in lymphocytes, normocytic monocytes, and eosinophils.

Cytology was the most efficient technique for the detection of canine mammary gland diseases. In the diagnosis of malignant lesions, it was especially helpful, followed by inflammatory and hyperplastic lesions. The cytology demonstrated 87.5% sensitivity and 85.7% specificity in identifying neoplasia, and there was a 70% concordance between cytology and histological results (Shivani, 2007). For canine mammary tumour, histopathology is regarded as the gold standard diagnostic technique (Rasotto *et al.,* 2017). Ovarian hormones, chiefly estrogens and progesterone, are recognized as pivotal in the development of canine mammary tumours (CMT) (Ali *et al.,* 2016).

Thoracic imaging needs to be conducted in all cases of mammary tumours in order to identify prevalent pulmonary metastases (Otoni *et al.,* 2010). Common imaging modalities for the detection of lung metastases include radiography, magnetic resonance imaging, and

Moreover, hormonal variables significantly contribute to the development of canine mammary gland tumours (Komazawa *et al.,* 2016). Salas *et al.* (2015) suggested that the natural estrogens in the mammary gland, which can promote cell proliferation and produce carcinogenesis, may be the cause of the higher risk of mammary gland neoplasm in females.

A minor reduction in platelet counts was seen in comparison to those of presumably healthy dogs. In canines affected by mammary gland tumour, serum biochemical estimations indicate an insignificant decrease in BUN values, as well as an insignificant increase in serum creatinine, ALT, AST, ALP, and total protein (Kumar *et al.,* 2018).

According to Garden *et al.* (2018), estrogens are initiators of cells and also regulate the transcription of many nuclear protooncogenes. Both benign and malignant tumours of the mammary gland exhibit estrogen receptors (ERs). In addition to its involvement in the early malignant transformation, the ER may also be a logical therapeutic target in canine mammary gland cancers (Canadas *et al.,* 2019). The pathogenesis of hormone-induced mammary neoplasia and the response to hormone therapy may also be impacted by the presence of estrogen or progesterone receptors (or both) on mammary cancer cells in animals (Kamble *et al.,* 2016).

computed tomography (CT) (Nemanic *et al.*, 2006; Shafer *et al.,* 2005). It has been discovered that radiology is a useful diagnostic tool for lung metastatic lesions. For detecting early and advanced stages of lung metastasis linked to breast and superficial neoplasms, thoracic radiography has been shown to be an economical, dependable, and time-efficient diagnostic technique.

Tamoxifen is currently prescribed for estrogen receptor positive breast carcinoma in women since research studies showed that it might decrease the development and recurrence of breast cancer in women (Quirke, 2017). Tamoxifen functions as an antagonist against ER in the mammary gland epithelium while acting as an agonist in the bone tissue matrix to support the maintenance of bone mineral density (Dowers *et al.*, 2006). Morris *et al.* (1993) have also recommended the use of tamoxifen, which has been demonstrated to be effective in the treatment of CMCs. Broparestrol, Raloxifene, and Toremifene are additional SERMs that are clinically offered to the medical management of mammary carcinoma (Oceguera *et al.*, 2020). Lonaprisan, a steroidal pure PR antagonist, demonstrated anti-proliferative action in the T47D breast cancer cell line by stopping the cells in the G0/G1 phase and causing a senescence-like phenotype (Busia *et al.*, 2011). Dogs are currently administered aglepristone, a competitive inhibitor of PR, which is a medication used to terminate pregnancy. Significant anti-proliferative activity against PR-positive CMTs was observed in studies on the impact of aglepristone on canine mammary neoplasms. On the other hand, both a clinical correlation and research involving a greater number of patients are required (Guil-Luna *et al.*, 2011). The predominant treatment employed is surgical excision; however, one particular procedure is not universally applicable to all individuals due to variations in tumour type and growth duration (Allen and Mahaffey, 1989).

References

Ali, M. R., Ibrahim, I. M., Ali, H. R., Selim, S. A., & El-Sayed, M. A. (2016).Treatment of natural mammary gland tumors in canines and felines using gold nanorods-assisted plasmonicphotothermal therapy to induce tumor apoptosis. *International journal of nanomedicine*, **11:** 4849-4863.

Allen SW, Mahaffey EA. Canine mammary neoplasia: prognostic indicators and response to surgical therapy. Journal of American Veterinary Medicine Association 1989;25(5):540-546.

Andrade, F. H., Figueiroa, F. C., Bersano, P. R., Bissacot, D. Z., & Rocha, N. S. (2010). Malignant mammary tumor in female dogs: environmental contaminants. *Diagnostic pathology*, ***5*:** 1-5.

Arya, S. K. D., Kumar, K., Kumar, D., Kumar, S., Tiwary, R., Sinha, M.,Yadav, S., Suman, S., Armanullah, M., Kumar, A., & Kumar, R. (2018). Incidence of commonly occurring neoplasms amongst canines in Patna. *International Journal of Current Microbiology and Applied Sciences*, ***7*(1):**2817-2823.

Bhanderi, D. R., Jhala, S. K., Suthar, D. N., Dabas, V. S., Bhatt A. B. & Patel, K. D. (2022).An epidemiological study of canine neoplasms. *The Pharma Innovation Journal*, **11(12)**: 1176-1178.

Busia, L., Faus, H., Hoffmann, J., & Haendler, B. (2011). The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by

inducing p21 expression. *Molecular and Cellular Endocrinology*, **333(1):** 37-46.

Canadas-Sousa, A., Santos, M., Leal, B., Medeiros, R., & Dias-Pereira, P. (2019).Estrogen receptors genotypes and canine mammary neoplasia. *BMC veterinary research*, **15:** 1-10.

Dowers, T. S., Qin, Z. H., Thatcher, G. R., & Bolton, J. L. (2006). Bioactivation of selective estrogen receptor modulators (SERMs). *Chemical research in toxicology*, **19(9):** 1125.

Garden, O. A., Volk, S. W., Mason, N. J., & Perry, J. A. (2018). Companion animals in comparative oncology: One Medicine in action. *The Veterinary Journal*, **240:** 6-13.

Guil-Luna, S., Sánchez Céspedes, R., Millan, Y., De Andres, F. J., Rollon, E., Domingo, V., & Martín de Las Mulas, J. (2011). Aglepristone decreases proliferation in progesterone receptor positive canine mammary carcinomas. *Journal of Veterinary Internal Medicine*, **25(3):** 518-523.

Kamble, M., Dhakate, M. S., Upadhye, S. V., &Akhare, S. B. (2016). Surgical management of mammary tumor in a dog. *Intas Polivet*, **17(1):** 196-197.

Komazawa, S., Sakai, H., Itoh, Y., Kawabe, M., Murakami, M., Mori, T., & Maruo, K. (2016).Canine tumor development and crude incidence of tumors by breed based on domestic dogs in Gifu prefecture.*Journal of Veterinary Medical Science*, **78(8)**: 1269-1275.

Kumar, K., Agrawal, R., Pande, N., Sharma, S., & Kumar, H. (2018). Occurrence, clinico-haemato-biochemical and histopathological studies on mammary gland tumor in geriatric dogs. *The Pharma Innovation*, ***7*(5, Part E):** 301.

Morris, J. S., J. M., Dobson, D. E. & Bostock. (1993). Use of tamoxifen in the control of mammary neoplasia, *Veterinary Record*, **133:** 539.

Nemanic, S., London, C.A. & Wisner, E.R. (2006).Comparison of thoracic radiographs and single breath-hold helical CT for detection of pulmonary nodules in dogs with metastatic neoplasia. *Journal of Veterinary Internal Medicine*, **20(3)**: 508-15.

Oceguera-Basurto, P., Topete, A., Oceguera-Villanueva, A., Rivas-Carrillo, J., Paz-Davalos, M., Quintero-Ramos, A., Del Toro-Arreola, A., & Daneri-Navarro, A. (2020). Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review. *Translational Cancer Research*, **9(7):** 4444.

Otoni, C. C., Rahal, S. C., Vulcano, L. C., Ribeiro, S. M., Hette, K., Giordano, T., Doiche, D. P., & Amorim, R. L. (2010). Survey radiography and computerized tomography imaging of the thorax in female dogs with mammary tumors. *Acta Veterinaria Scandinavica*, **52:** 1-10.

Quirke, V. M. (2017). Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation. *Frontiers in pharmacology*, **8:** 620.

Rasotto, R., Berlato, D., Goldschmidt, M. H., & Zappulli, V. (2017). Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases. *Veterinary pathology*, **54(4):** 571–578.

Ray, K., Jha, A. K., Mandal, A., & Mandal, D. (2021). Clinico-pathological Studies on Canine Mammary Tumors in Dachshund Dog. *Indian Journal of Animal Research*, **56 (3):** 336-341.

Rungsipipat, A., Sunyasootcharee, B., Ousawaphlangchai, L., Sailasuta, A., Thanawongnuwech, R., &Teankum, K. (2003). Neoplasms of dogs in Bangkok. *The Thai Journal of Veterinary Medicine*, ***33*(1):** 59-66.

Salas, Y., Márquez, A., Diaz, D., & Romero, L. (2015). Epidemiological study of mammary tumors in female dogs diagnosed during the period 2002-2012: a growing animal health problem. *PloS one*, ***10*(5):** e0127381.

Schäfer, J. F., Vollmar, J., Schick, F., Seemann, M. D., Kamm, P., Erdtmann, B., &Claussen, C. D. (2005). Detection of pulmonary nodules with breath-hold magnetic resonance imaging in comparison with computed tomography. *Rofo: Fortschritte auf demGebiete der Rontgenstrahlen und der Nuklearmedizin*, **177(1):** 41-49.

Schneider, R., Dom, C. R., & Taylor, D. O.N. (1969).Factors influencing canine mammary cancer development and postsurgical survival. *Journal of the National Cancer Institute,* **43:** 1249-1261

Shivani. (2007). Cytopathology of canine mammary gland affections with special reference to mammary gland tumours. M.V.Sc Thesis, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, India.

Tanaka, M., Yamaguchi, S., & Iwasa, Y. (2020).Enhanced risk of cancer in companion animals as a response to the longevity. *Scientific reports*, **10(1):** 19508.